Purple Biotech (NASDAQ:PPBT – Free Report) had its price target hoisted by HC Wainwright from $8.00 to $33.00 in a research report sent to investors on Friday, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Purple Biotech’s Q3 2024 earnings at ($1.20) EPS, Q4 2024 earnings at ($0.62) EPS, FY2025 earnings at ($2.19) EPS, FY2026 earnings at ($2.05) EPS, FY2027 earnings at ($1.88) EPS and FY2028 earnings at ($1.81) EPS.
Purple Biotech Price Performance
Shares of NASDAQ PPBT opened at $6.89 on Friday. Purple Biotech has a 1-year low of $6.05 and a 1-year high of $36.00. The firm has a market cap of $173.89 million, a price-to-earnings ratio of -8.51 and a beta of 1.07.
Purple Biotech (NASDAQ:PPBT – Get Free Report) last announced its quarterly earnings data on Friday, August 16th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. Analysts anticipate that Purple Biotech will post -0.32 earnings per share for the current year.
Hedge Funds Weigh In On Purple Biotech
Purple Biotech Company Profile
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.
Featured Stories
- Five stocks we like better than Purple Biotech
- How to Use the MarketBeat Excel Dividend Calculator
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- How Technical Indicators Can Help You Find Oversold Stocks
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Purple Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Purple Biotech and related companies with MarketBeat.com's FREE daily email newsletter.